IMM 1.49% 34.0¢ immutep limited

Ann: Immutep announces Ph 3 clinical trial collaboration with MSD, page-12

  1. 7,886 Posts.
    lightbulb Created with Sketch. 62
    I would think only for NSCLC as that is the trial that hopefully gets FDA approval. However as an acquisition of IMM then Merck get the full range of every other trial that is underway. If HNSCC trial is successful prior to the NSCLC then that just bumps up the acquisition price.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.